9,096 Shares in Lantheus Holdings, Inc. $LNTH Acquired by Havemeyer Place LP

Havemeyer Place LP acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, HoldingsChannel reports. The firm acquired 9,096 shares of the medical equipment provider’s stock, valued at approximately $605,000.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Lantheus by 1.7% in the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after purchasing an additional 115,338 shares during the period. M&T Bank Corp purchased a new stake in shares of Lantheus during the fourth quarter valued at $370,950,000. Reinhart Partners LLC. grew its holdings in shares of Lantheus by 15.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock worth $103,990,000 after purchasing an additional 214,820 shares during the last quarter. Norges Bank bought a new position in shares of Lantheus in the fourth quarter worth about $76,197,000. Finally, TD Asset Management Inc increased its stake in Lantheus by 25.0% in the 3rd quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock worth $40,568,000 after buying an additional 158,358 shares during the period. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on LNTH shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Jefferies Financial Group restated a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research note on Tuesday, March 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Truist Financial reaffirmed a “buy” rating and set a $115.00 price target (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Finally, Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Performance

LNTH stock opened at $100.01 on Tuesday. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $104.00. The business has a 50-day moving average price of $88.48 and a 200 day moving average price of $75.44. The company has a market capitalization of $6.51 billion, a P/E ratio of 24.10 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same period in the prior year, the business earned $1.53 EPS. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 4.42 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.